The antibody developed against the Ubl4A protein is available for licensing. Ubl4A is involved in the proper targeting of tail-anchored proteins to membranes by acting as a chaperone to prevent inappropriate interactions or aggregation. Alterations in membrane insertion or protein degradation may be related to Ubl4a in certain disease states making Ubl4a an attractive biomarker for the study of disease development or as a tool for the development of assays for disease detection.
CRADA Opportunity: The NICHD is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize Ubl4A assay detection for disease diagnostics. Please contact Charlotte McGuinness at 301-435-3130 or
mcguinnc@mail.nih.gov for more information.
Source: http://www.ott.nih.gov/Technologies/abstractDetails.aspx?RefNo=2282
Elisha Cuthbert Eliza Dushku Emilie de Ravin Emma Heming Emma Stone
No comments:
Post a Comment